Skip to content
DataLookout
Menu

Pro-HealthNCT06198374

Impact of Propionic Acid on Regulatory T Cell Function in Healthy Adults ( Pro-Health)

StatusActive, Not Recruiting
PhaseNot applicable
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 13 words
    • Study completion pushed from May 30, 2025 to Jan 30, 2027
    • Secondary endpoints: details revised at 2 of 9 entries
    • Site details revised
  2. Minor Study completion date: Oct 30, 2024 to May 30, 2025v4
  3. Minor Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Jun 30, 2024 to Oct 30, 2024
    • Secondary endpoints: 6 to 9
    • Site details revised
    v3
  4. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Jan 1, 2024 to Jan 8, 2024
    • Secondary endpoints revised (6)
    v2
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Change in count of regulatory T-cells from baseline to week 4
Timeframe: Baseline visit (week 0) in comparison to week 4

Secondary (9)

Propionic acid serum levels and targeted metabolomics
Relative abundance of different immune cell subsets with Immune cell phenotyping of peripheral blood mononuclear cells (PBMC)
Measuring the suppressive function of regulatory T cells (Tregs) as percentage of proliferated conventional CD4-positive T cells with an in vitro T regulatory cell (Treg) suppression assay
Single cell RNA sequencing of immune cells
Measuring the intestinal barrier function by measuring the concentration of different leaky gut markers
Show 4 moreShow less
Taxonomy of the fecal microbiome
Cardiovascular Phenothyping
Cardiovascular Phenotyping
Cholesterol levels

Arms and interventions

PA Intervention.Experimental

The group which receives the PA as a dietary food supplement. A single capsule contains 500mg of sodiumpropionate, which is taken twice daily for 28 days.

Placebo InterventionPlacebo comparator

The control-group receives a placebo instead of propionate. The placebo contains maltodextrin and the same amount of sodium chloride as compared to the PA intervention. The placebo is taken twice per day for 28 days.

Dietary supplements: Sodium propionate

Other: Placebo

Sites

1 site in 1 country

  • Department of Pediatric Gastroenterology, Nephrology and Metabolic Diseases, Charité-Universitätsmedizin BerlinBerlin, State of Berlin, Germany